USC and second sight announce European clinical trial for Argus II retin... (sity of Southern California (USC) Wilmer...)

USC and second sight announce European clinical trial for Argus II retinal implant

Date:2/15/2008

sity of Southern California (USC), Wilmer Eye Institute at Johns Hopkins University (Baltimore), the University of California at San Francisco, and the Retina Foundation of the Southwest (Dallas). Second Sight will be seeking expansion of the U.S. trial to include other trial sites located in New York (Columbia University Medical Center and Lighthouse International), Philadelphia (Scheie Eye Institute and Wills Eye Hospital) and Atlanta (Emory University and Atlanta V.A. Rehab R&D Center). This three-year Investigational Device Exemption (IDE) trial is the only long-term study of a retinal prosthesis currently being conducted anywhere in the world.

Internationally, the Argus II study began in Mexico in the fall of 2006 at Centro de Retina Medica y Quirurgica, SC, Centro Medico Puerta de Hierro, CUCS, Universidad de Guadalajara (Guadalajara, Jal.). More recently, enrollment has just begun at two European sites, including Service dOphtalmologie, Hpital Cantonal, Universitaire de Genve (Geneva, Switzerland) and Le Centre Hospitalier National DOphtalmologie Des Quinze-Vingts (Paris, France). A third study site at Moorfields Eye Hospital in London has recently received government approval and is expected to begin enrollment shortly.

The pioneering efforts of the individuals that participate in this clinical trial will lead to advances for the many people in the world afflicted with blindness, said Mark Humayun, MD, PhD, Professor of Ophthalmology, Biomedical Engineering, and Cellular and Neurobiology at the Doheny Eye Institute, Keck School of Medicine of USC, and Viterbi School of Engineering and the first physician to perform an Argus II implantation procedure in the US.

Dr. Humayun was the vitreo-retinal surgeon for the first generation 16-electrode (Argus 16), which he implanted in six RP subjects between 2002 and 2004. The study demonstrated the ability of participants to detect when lights are on or off, describe an objects motion, cou
'/>"/>

Contact: Jon Weiner
jon.weiner@usc.edu
323-442-2830
University of Southern California
Source:Eurekalert

1

GOOD

Page: 1 2 3
Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
2. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
3. Escalon(R) Reports Second Quarter Fiscal 2008 Results
4. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
5. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
6. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
7. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
8. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
9. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
10. Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008
11. Neurobiological Technologies Sets Date for Second Quarter Financial Results

Post Your Comments:

(Date:5/15/2012)... AUSTIN, Texas, May 15, 2012 Vermillion, Inc. ... company, reported financial and operational results for the first ... Operational Highlights , In Q1, the volume ... help differentiate benign from malignant ovarian masses, was generally ... the quarter and demonstrated an increase of 28% to ...

(Date:5/15/2012)... 2012 Reportlinker.com announces that ... available in its catalogue: , ... and Market Forecast to 2019 ... Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment ... Summary GlobalData, the industry analysis ...

(Date:5/15/2012)... May 15, 2012 Generex Biotechnology Corporation (OTCBB: ... pivotal Phase III trials, is pleased to announce today ... of its wholly-owned subsidiary, Antigen Express, Inc., has been ... in clinical trial research and immuno-therapeutic treatments of breast ... Indiana University School of Medicine ...

(Date:5/15/2012)... BGI, one of the world,s ... GS FLX+ System has been successfully installed at its ... the existing array of short read sequencing technologies and ... GS FLX+ System, developed by 454 Life Sciences, a ... exceptional accuracy and high-throughput, making the system well suited ...

[0] Vermillion Reports First Quarter 2012 Results [0] Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 [0] Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers [0] BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research

... April 30 Tigris Pharmaceuticals, Inc., a privately held ... on its novel molecule, AFP-464, during the recent AACR ... represents a significant advancement in the treatment of Triple ... of invasive breast cancer," stated Edmundo Muniz, M.D., Ph.D., ...

... Educational Webinar "How Organizations Can Make the Transition to ... Virtify, Inc. , , CAMBRIDGE, Mass., April ... the market leader in Enterprise Content Compliance solutions for ... ), a provider of Enterprise Compliance and Quality Management ...

... 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... for the first quarter ended March 31, 2009. , ... first quarter in what has been a difficult business ... and CEO of Angiotech. "Sales in our proprietary Surgical ...

Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes'Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009

(Date:5/21/2012)... Institution (WHOI) have conducted a new study to measure ... Ocean. The study, recently published in the journal ... understand the Arctic Ocean,s carbon cyclethe pathway through which ... It will also offer an important point of reference ... time, and how the ecosystem responds to rising global ...

(Date:5/21/2012)... Woesik, Florida Institute of Technology professor of biological ... the National Science Foundation for research into the ... develop quantitative approaches to assess the clustering of ... the corals. When diseases cluster they are usually ... cause of infection., Although diseases are one of ...

(Date:5/21/2012)... the National University of Singapore,s (NUS) Department of Biological ... compound a compound that is undergoing preclinical trials ... of energy and stop them from growing into a ... This is the first time a research group has ... formation. , Building on the new findings, the ...

Breaking Biology News(10 mins):New study by WHOI scientists provides baseline measurements of carbon in Arctic Ocean 2 New study by WHOI scientists provides baseline measurements of carbon in Arctic Ocean 3 Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2 Many Parents in the Dark About Drug Resistant Infections 3A Study 76703 1 Many Parents in the Dark About Drug Resistant Infections 3A Study 76703 2 Former FDA Inspectors Train Medical Device Pharmaceutical Companies How to Comply with Latest FDA Expectations for Validation and Part 11 17786 1 Former FDA Inspectors Train Medical Device Pharmaceutical Companies How to Comply with Latest FDA Expectations for Validation and Part 11 17786 2 Regenicin to Present Live at RetailInvestorConferences com on November 4th 17784 1 Regenicin to Present Live at RetailInvestorConferences com on November 4th 17784 2

[0] New study by WHOI scientists provides baseline measurements of carbon in Arctic Ocean [0] Florida Tech biological sciences professor earns $257,000 NSF grant to study coral diseases [0] Novel discovery by NUS scientists paves the way for more effective treatment of cancers

... requires many years of growth before a tree is ready ... Now, scientists at universities in Sweden and the United States ... , In the annual plant Arabidopsis, the first plant to ... Locus T (FT) induce flowering in response to day length. ...

... ants, most people prefer to wipe the venomous little varmints off ... own back yards. The reviled South American native that invaded the ... circles as Solenopsis invicta and everywhere else as a painful pest ... Tschinkel. , An ardent fire ant fan and one of its ...

... a lawnmower, the Holy Grail of horticultural accomplishment would be ... Now, that vision of suburban bliss -- and more -- ... pathway that regulates the stature of plants. In addition to ... the development of sturdier, more fruitful crop plants such as ...

Other Biology News:Scientists discover that ancient genes dictate flowering, fall bud set 2 Fire ants: Their true story told by the scientist who loves them 2 Fire ants: Their true story told by the scientist who loves them 3 No-mow grass may be coming to your yard soon 2 No-mow grass may be coming to your yard soon 3

Scientists discover that ancient genes dictate flowering, fall bud set Fire ants: Their true story told by the scientist who loves them No-mow grass may be coming to your yard soon

...

Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...

Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...

Biology Products:

Acrylamide, Molecular Biology Grade from Research Organics, Inc.Acrylamide from Research Organics, Inc.Rabbit Anti-XTP4 Polyclonal Antibody, Unconjugated from Abcam Chicken Anti-Human QPRT Polyclonal Antibody, Unconjugated from Abcam

USC and second sight announce European clinical trial for Argus II retin...(sity of Southern California (USC) Wilmer...)